|FDA Proposes New Division, Office of Pharmaceutical Quality (OPQ)|
FDA Proposes New Division, Office of Pharmaceutical Quality (OPQ)
The Food and Drug Administration (FDA) is ramping up preparations for a proposed a new division, the Office of Pharmaceutical Quality (OPQ), within its Center for Drug Evaluation and Research (CDER). The new office would exercise authority over the pharmaceutical manufacturing process throughout a product’s entire life cycle, taking over and consolidating some responsibilities from the existing Office of Manufacturing and Product Quality and the Office of Pharmaceutical Science. The FDA says OPQ is intended to become a “global benchmark for regulation of pharmaceutical quality,” that will oversee the full spectrum of medicines, including brand-name, generic, and over-the-counter drugs.
At a panel during the Biotechnology Industry Organization’s annual convention on June 24, Russell Wesdyk, scientific coordinator for the FDA’s Office of Pharmaceutical Science, stressed that the FDA doesn’t intend to replace existing regulations but rather is looking to sharpen its focus under the existing regulatory umbrella. Read more on OPQ.
Tell us how compounded pharmaceuticals have helped you, someone you know, or how you have helped someone as a practicing compounding pharmacist. Help us protect your continued access to pharmacy compounding!
Share the P3 community and the value and necessity of personalized prescriptions with your friends.